bioMérieux S.A. (BMXXY)
OTCMKTS · Delayed Price · Currency is USD
14.62
+0.79 (5.71%)
At close: Aug 5, 2025
bioMérieux Revenue
bioMérieux had revenue of 2.04B EUR in the half year ending June 30, 2025, with 15.46% growth. This brings the company's revenue in the last twelve months to 4.12B, up 8.28% year-over-year. In the year 2024, bioMérieux had annual revenue of 3.98B with 8.31% growth.
Revenue (ttm)
4.12B EUR
Revenue Growth
+8.28%
P/S Ratio
3.26
Revenue / Employee
279.37K EUR
Employees
14,754
Market Cap
15.78B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.98B | 305.20M | 8.31% |
| Dec 31, 2023 | 3.67B | 85.60M | 2.39% |
| Dec 31, 2022 | 3.59B | 212.90M | 6.31% |
| Dec 31, 2021 | 3.38B | 258.00M | 8.27% |
| Dec 31, 2020 | 3.12B | 443.40M | 16.58% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Tian'an Technology Group | 2.12M |
| Elite Pharmaceuticals | 105.45M |
| Glass House Brands | 221.55M |
| Northwest Biotherapeutics | 1.09M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.17M |
| AMJ Global Technology | 39.00 |
bioMérieux News
- 13 days ago - BioMérieux S.A. (BMXXY) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - bioMérieux S.A. 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 7 months ago - bioMérieux S.A. (BMXMF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 1 year ago - bioMérieux S.A. (BMXMF) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 years ago - bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2021 Results - Earnings Call Transcript - Seeking Alpha
- 4 years ago - bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q3 2021 Results - Earnings Call Transcript - Seeking Alpha
- 4 years ago - bioMérieux: Pioneering In Vitro Diagnostics - Seeking Alpha
- 4 years ago - bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2020 Results - Earnings Call Transcript - Seeking Alpha